Aurobindo Pharma Limited, one of the country’s leading pharmaceutical companies has joined hands with Citadel Fine Pharmaceuticals Limited (CFPL) to promote Citadel Aurobindo Biotech Limited (CABL) – a 50-50 joint venture. CABL will combine the strengths and talent of two extremely strong pharmaceutical houses, with a proven track record.

The joint venture commences operations with four lines of branded formulations for the domestic ethical markets. The Citadel Division will take over identified branded formulation line of CFPL while Aurobindo Pharma will transfer identified branded formulations lines to this new company. Citadel brands shall contribute around 70% of the turnover while the rest comes from Aurobindo Pharma Limited.

CABL would focus on specific therapeutic areas like cardiovascular, diabetology, gastroenterology, infection, nutrition and pain management. The new joint venture expects a turnover of about Rs.135 crore in its first year of operations. 

CABL is well positioned to achieve high growth rates given the combined strengths that the two partners bring to this joint venture.

CABL will have an 800 field force strength with excellent network of over 1500 stockists, distributors and C & F agents.

The Company will thus start out with an enormous marketing and distribution network, top-notch formulation research and development capabilities and an excellent pipeline of new generation molecules. In addition, substantial cost synergies will take place in the areas of finance, administration, distribution and services.

CFPL is a 40 year old well established pharma company with a strong marketing and distribution network and a portfolio of brands that will bring enormous value to the joint venture. Aurobindo Pharma is a Rs.1000 crore pharma major with proven R&D led capabilities in introducing complex, new generation drugs.